Case No Country Mandate(s) Summary of the allegation transmitted IND 4/2013 08/03/2013 India JAL Freedom of expression; Human rights defenders; Minority issues; Summary executions; Alleged killing of Mr. Gaikwad, a human rights defender who reportedly registered and followed-up on cases of Dalits who had been the victims of caste-based discrimination when trying to access justice and worked as a volunteer with the National Dalit Movement for Justice, monitoring and documenting violations on the basis of caste; and attempted killing of another defender, Mr. Dada Shivaji Jadhav. According to the information received, on 12 February 2013, human rights defender Mr. Chandra Kant Gaikwad was fatally shot by unidentified persons while visiting a fellow human rights defender, Mr. Dada Shivaji Jadhav, who managed to escape alive. The unidentified perpetrators are reported to have arrived on a jeep. It is reported that Mr. Gaikwad, Mr. Jadhav and a third human rights defender, Mr. Vaibhav Gite, had received threats from a man in relation to whom they had filed a complaint alleging crimes committed against Dalits. OTH 2/2013 08/03/2013 Other OL Health; Concerning the request from the delegation of Haiti to the WTO Council for TradeRelated Aspects of Intellectual Property Rights (TRIPS Council) for an extension of the transitional period granted under article 66 of the Agreement for least developed country (LDC). On behalf of LDC members, the request reportedly seeks an unconditional and extension of the transitional period (that ends on 1 July 2013) and the waiver from implementing or enforcing patents and test data obligations with regard to pharmaceutical products (that expires on 1 January 2016) for as long as the WTO Member remains a least developing country. LDC Members are characterized by high rates of poverty and high burden of communicable and non-communicable diseases. Without the extension of the transition period, LDC members would be required to adopt and enforce strict intellectual property laws with neither the support of a sufficiently strong economy nor the presence of adequate infrastructure and capacity. The consequent increase in medicine prices would become a serious barrier to access to medicines, including essential medicines, by those who require them most. Reply A/HRC/24/21 12 Date Type